国际商务管理 社会学心理学 信息和知识管理 管理类作业 经济学作业 法律作业 市场学作业 语言学作业 金融作业格式 会计作业格式 物流管理作业
返回首页

产品知识产权技术协议写作方法


        Patents may not enable us to preclude competitors from commercializing drugs in direct competition with our products, and
consequently may not provide us with any meaningful competitive advantage. See Risk Factors.

我们的产品商业化的药物专利可能不能使我们排除竞争对手直接竞争,因此,可能没有为我们提供任何有意义竞争优势,c存在风险因素
         We are aware of intellectual property rights held by third parties that relate to products or technologies we are developing. For
example, we are aware of others investigating methylnaltrexone and other peripheral opioid antagonists as well as PSMA or related
compounds, and of patents and applications held or filed by others in those areas.
我们都意识到相关的产品或技术的重要性,我们正在开发使用第三方持有的知识产权例如,我们都知道甲基纳曲酮和其他外围阿片受体拮抗剂以及PSMA相关化合物,以及他人持有或申请在这些领域专利和应用
While the validity of issued patents, patentability of claimedinventions in pending applications and applicability of any of them to our programs
are uncertain, patent rights asserted against us couldadversely affect our ability to commercialize or collaborate with others regarding our products.

          Research, development and commercialization of a biopharmaceutical product often require choosing between alternative
development and optimization routes at various stages in the development process. Preferred routes depend upon subsequent discoveries and
test results and cannot be identified with certainty at the outset. There are numerous third-party patents in our field, and we may need to obtain
a license under a patent in order to pursue the preferred development route of one or more of our product candidates. The need to obtain a
license would decrease the ultimate profitability of the applicable product. If we cannot negotiate a license, we might have to pursue a less
desirable development route or terminate the entire program altogether.http://ukthesiss.com/Thesis_Tips/

Government Regulation 政府条例

          Progenics and its product candidates are subject to comprehensive regulation by the U.S. FDA and comparable authorities in other
countries. Pharmaceutical regulation currently is a topic of substantial interest in lawmaking and regulatory bodies in the U.S. and
internationally, and numerous proposals exist for changes in FDA and non-U.S. regulation of pre-clinical and clinical testing, safety,
effectiveness, approval, manufacture, labeling, marketing, export, storage, recordkeeping, advertising, promotion and other aspects of
biologics, small molecule drugs and medical devices, many of which, if adopted, could significantly alter our business and the current
regulatory structure described below. See Risk Factors.

         FDA Regulation. FDA approval of our product candidates, including a review of the manufacturing processes and facilities used to
produce them, are required before they may be marketed in the U.S. This process is costly, time consuming and subject to unanticipated delays,
and a drug candidate may fail to progress at any point.

         None of our product candidates other than RELISTOR has received marketing approval from the FDA or any other regulatory



------分隔线----------------------------
UK Thesis Base Contacts

24小时在线客服

QQ:77276002

Email:77276002@qq.com

推荐内容